This clinical testing protocol outlines the validation process for an epigenetic assay targeting host peripheral blood cell and the associated host DNA methylation signatures designed to diagnose pancreatic cancer. The overall protocol process will involve three distinct stages representing three patient cohorts with up to 150 subjects per cohort across 3 populations of patients. Cohort one will act as signature development phase; cohort two will act as signature finalization phase; and cohort three will act as a validation cohort phase. Each cohort with include the following patient populations with up to 50 patients per population:
1. Pancreatic cancer, NO chemotherapy. Surgical resection and/or radiation therapy
2. Pancreatic cancer, WITH chemotherapy. All stages including remission
3. At risk group (individuals who have chronic pancreatitis, been diagnosed with an intraductal papillary mucinous neoplasm (IPMN), have a family history of pancreatic cancer and/or have a known genetic disposition)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years old or older
Patient of UMMS
Willing and able to consent to study procedures listed in the protocol
Ability to speak and understand English
Has a history of pancreatic cancer of is at high risk for pancreatic cancer
You may not be if
Younger than 18 years old
Patient not cared for at UMMS
Unable to consent to study procedures listed in the protocol
Unable to speak or understand English
Does not have a history of pancreatic cancer or is not at high risk for pancreatic cancer